Volume 96, Issue 11 pp. 3052-3071

Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery

Liping Zhou

Liping Zhou

PreClinical Profiling, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139

Search for more papers by this author
Linhong Yang

Linhong Yang

PreClinical Profiling, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139

Search for more papers by this author
Suzanne Tilton

Suzanne Tilton

PreClinical Profiling, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139

Search for more papers by this author
Jianling Wang

Corresponding Author

Jianling Wang

PreClinical Profiling, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139

PreClinical Profiling, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139. Telephone: 617-871-7140; Fax: 617-871-7061.Search for more papers by this author
First published: 25 September 2007
Citations: 16

Abstract

Increasingly, pharmaceutical and biotech companies have begun to realize the importance of obtaining solubility information in early drug discovery as it is one of the critical parameters for lead selection and optimization. This report introduces a high-throughput equilibrium solubility (HT-Eq sol) assay using a novel miniaturized shake-flask approach and streamlined HPLC analysis. The new HT-Eq sol assay, validated and optimized via a test set of 85 marketed drugs and Novartis internal compounds, shows an excellent correlation to the conventional shake-flask thermodynamic solubility data generated in-house and the equilibrium solubility results reported in literature. It therefore offers a fast, reliable and cost-effective screening tool for solubility assessment in early drug discovery, allowing for prioritization of drug candidates using aqueous solubility in conjunction with other profiling information and efficacy data. Our work demonstrates that presence of a small amount of DMSO (0.5–5%) will result in significant overstimation of equilibrium solubility (up to 6 folds). In addition, monitoring of drug dissolution process using the current approach as well as the interplay between equilibrium solubility data and those from kinetic solubility are discussed. © 2007 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 96: 3052–3071, 2007

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.